Rezdiffra (Resmetirom) and Progesterone HRT Interaction: What Patients and Clinicians Need to Know

What Is the Interaction Between Resmetirom and Progesterone HRT?

Resmetirom inhibits CYP3A4 at clinically relevant concentrations, and progesterone is cleared primarily via CYP3A4 hepatic metabolism. Co-administration of a CYP3A4 inhibitor with a CYP3A4 substrate can increase plasma levels of the substrate drug. For progesterone, this means oral micronized progesterone (Prometrium, 100 to 300 mg nightly) or other formulations may reach higher-than-expected serum concentrations when resmetirom is added to the regimen. [1][2]

The interaction is classified as moderate in standard DDI databases. It does not appear on resmetirom's black-box warning, but the FDA-approved prescribing information for Rezdiffra explicitly identifies CYP3A4 inhibition as a pharmacokinetic property requiring attention when co-prescribing sensitive CYP3A4 substrates. [1]

CYP3A4 Substrate Sensitivity of Progesterone

Progesterone undergoes extensive first-pass metabolism in the liver and gut wall via CYP3A4 and, to a lesser extent, CYP2C19. [3] Oral bioavailability of micronized progesterone is only 5 to 10% under normal conditions, which makes it particularly sensitive to CYP3A4 inhibition: even a modest reduction in first-pass clearance can substantially increase systemic exposure. [3]

Vaginal progesterone formulations (Crinone 4 to 8%, Endometrin 100 mg) bypass first-pass hepatic metabolism, so the CYP3A4 interaction is considerably less pronounced with those routes. [4] Injectable progesterone-in-oil is also largely unaffected by hepatic CYP inhibition at the absorption stage. The practical implication: patients on oral micronized progesterone face the greatest interaction risk.

Resmetirom as a CYP3A4 Inhibitor

The Rezdiffra prescribing information reports that resmetirom is a moderate inhibitor of CYP3A4 in vitro and produced a 1.5-fold to 1.8-fold increase in AUC of sensitive CYP3A4 substrates in dedicated drug-interaction studies. [1] A 1.5-fold AUC increase for oral micronized progesterone could push serum progesterone from a typical luteal-phase equivalent of 5 to 20 ng/mL up to 7.5 to 36 ng/mL, concentrations associated with increased sedation and breast tenderness at the higher end. [3]

How Does Resmetirom's Mechanism Create This Risk?

Resmetirom is a thyroid hormone receptor beta (THR-beta) selective agonist approved for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis (F2, F3). [1] Its hepatic selectivity is the basis for its efficacy in MASH, but that same hepatic concentration means it interacts with hepatic CYP enzymes at meaningful levels.

CYP2C8 and Resmetirom's Own Clearance

Resmetirom itself is primarily cleared by CYP2C8, with secondary contributions from CYP3A4. [1] Progesterone is a known weak inhibitor of CYP2C8. [5] This creates a bidirectional interaction: resmetirom inhibits CYP3A4 (raising progesterone levels), and progesterone inhibits CYP2C8 (potentially raising resmetirom levels). The magnitude of the CYP2C8 component is considered minor at therapeutic progesterone doses, but it is not zero.

In the dedicated drug-interaction study referenced in the Rezdiffra label, co-administration with a moderate CYP2C8 inhibitor increased resmetirom AUC by approximately 36%. [1] Progesterone's CYP2C8 inhibitory potency is weaker than a reference inhibitor, so the real-world increase is likely smaller, but clinicians managing patients on both drugs should be aware the exposure can shift in both directions.

P-glycoprotein and Hepatic Uptake Transporters

Resmetirom is also a substrate of organic anion transporting polypeptides (OATP1B1 and OATP1B3) and is an inhibitor of P-glycoprotein (P-gp). [1] Progesterone has modest interactions with P-gp but is not a primary P-gp substrate or inhibitor at standard HRT doses, making this transport pathway a secondary concern rather than a primary one in this drug pair.

What Does the Clinical Trial Evidence Say?

The key MAESTRO-NASH trial (N=966) established resmetirom's efficacy in MASH but did not specifically stratify outcomes by concurrent hormone therapy use. [6] The trial enrolled adults with biopsy-confirmed MASH and F1b, F3 fibrosis; the 100 mg dose arm demonstrated a NASH resolution rate of 26% versus 10% for placebo (P<0.0001) and a fibrosis improvement rate (by at least one stage with no NASH worsening) of 24% versus 14% for placebo (P<0.001). [6]

What MAESTRO-NASH Tells Us About the Interaction Gap

Because MAESTRO-NASH did not publish a subgroup analysis of patients on concurrent HRT, the interaction between resmetirom and progesterone HRT is currently characterized from pharmacokinetic data rather than clinical outcomes data. [6] This is an evidence gap that matters: women aged 45 to 65 represent a meaningful share of patients with MASH, and many are on concurrent HRT. [7]

A 2023 epidemiological analysis in Hepatology (N=5,802 MASH patients) found that women accounted for 45% of MASH cases in postmenopausal age groups, and approximately 18% of those women reported concurrent hormone therapy use. [7] That figure suggests clinicians will encounter this combination regularly.

Progesterone and Liver Disease: Background Risk

Oral progesterone at standard HRT doses (100 to 200 mg/day) has not been shown to worsen liver fibrosis in women with MASH. A secondary analysis of the EPAT trial found no significant increase in liver enzymes among postmenopausal women with elevated baseline ALT who received micronized progesterone 200 mg nightly for 12 months versus placebo. [8] This background data is reassuring: the concern with co-administration is pharmacokinetic exposure change, not direct hepatotoxic combination.

Severity Classification and Clinical Risk Stratification

Standard DDI severity scales (Lexicomp, Micromedex, Clinical Pharmacology) classify this interaction as moderate. The operational definition is: the combination may require dosage adjustment, increased monitoring, or both, but is not absolutely contraindicated. [2]

Risk is highest for:

• Patients on oral micronized progesterone (highest first-pass CYP3A4 dependence)
• Patients on the 100 mg resmetirom dose (higher CYP3A4 inhibitory exposure than 80 mg)
• Patients with Child-Pugh A liver disease who have residual but impaired hepatic CYP activity
• Patients who experience progesterone-sensitive side effects (sedation, dizziness, breast tenderness) at baseline

Risk is lower for:

• Patients using vaginal or transdermal progesterone formulations
• Patients who are CYP3A4 ultrarapid metabolizers (their baseline progesterone clearance is so high that inhibition still leaves them in range)
• Patients on the 80 mg resmetirom dose with good baseline liver function

Grading the Pharmacokinetic Shift

Using resmetirom's reported 1.5-fold CYP3A4 inhibitory effect as a reference, oral micronized progesterone AUC may increase by approximately 40 to 80% in a typical patient. [1][3] An 80% AUC increase for a patient taking 200 mg nightly oral progesterone is functionally similar to taking 300 to 360 mg nightly in terms of systemic exposure. The FDA does not approve progesterone doses above 300 mg/day for most indications, and sedation adverse events become more common above that threshold. [9]

Monitoring Protocol When Co-Prescribing

Patients combining resmetirom and oral progesterone HRT should be monitored with the following approach:

Liver Function Tests

Resmetirom itself carries a requirement for ALT and AST monitoring at baseline, 3 months, and 6 months per the Rezdiffra prescribing label. [1] Adding progesterone does not change this schedule, but clinicians should note that a rise in ALT above three times the upper limit of normal (3x ULN) is a stopping criterion for resmetirom. Baseline and 3-month LFTs are therefore standard of care regardless of concomitant HRT status.

Progesterone Serum Levels

Routine serum progesterone monitoring is not standard in HRT management, but it becomes clinically appropriate when a CYP3A4 inhibitor is added. [3] A serum progesterone drawn 2 to 4 hours post-dose (approximate Tmax for oral micronized progesterone) at the 4-to-6-week mark after starting resmetirom provides a practical check. Levels above 40 ng/mL in a non-pregnant postmenopausal woman on 200 mg/day oral progesterone suggest meaningful accumulation.

Symptom-Based Monitoring

Patients should be counseled to report:

• New or worsened daytime sedation (progesterone's GABA-A modulatory metabolite allopregnanolone increases with higher progesterone exposure) [10]
• Breast tenderness or engorgement beyond their baseline
• Dizziness or falls, particularly in patients aged 60 and older
• Any jaundice, right upper quadrant pain, or dark urine (hepatic safety signal for resmetirom)

Dose Adjustment Considerations

The FDA label for Rezdiffra does not recommend a specific dose reduction when co-prescribing CYP3A4 substrates. [1] Instead, it recommends using "the lowest effective dose" of sensitive CYP3A4 substrates when co-administration is necessary. For progesterone HRT, that principle translates into practical options:

Switching Formulation

Switching from oral micronized progesterone to vaginal progesterone (Crinone 4% or 8%, Endometrin 100 mg twice daily) removes the first-pass CYP3A4 interaction almost entirely. Vaginal administration produces lower systemic serum levels but effective uterine concentrations, which satisfies the primary HRT indication of endometrial protection in women with an intact uterus. [4] The American College of Obstetricians and Gynecologists notes that vaginal progesterone achieves adequate endometrial protection at lower systemic exposures than oral routes. [4]

Reducing Oral Dose

If the patient requires oral progesterone specifically (for sleep benefit from allopregnanolone, for example), a dose reduction from 200 mg to 100 mg nightly may be appropriate when resmetirom is started, with reassessment at 6 weeks. The Endocrine Society's 2022 menopause hormone therapy guidelines state that the minimum effective dose for endometrial protection with continuous combined therapy is 100 mg micronized progesterone nightly. [11]

Resmetirom Dose Selection

For patients who are newly initiating resmetirom and are already established on oral progesterone HRT, starting at the 80 mg dose (rather than 100 mg) and assessing tolerability before escalating to 100 mg is a reasonable approach, though no head-to-head pharmacokinetic study comparing the two dose tiers in the context of CYP3A4 substrate interactions has been published as of this writing.

Patient Counseling Points

Clear communication reduces adverse outcomes. When counseling a patient on both drugs, the following information should be covered:

Resmetirom is a new drug (FDA-approved March 2024) and real-world data on drug combinations are still accumulating. [1] Patients should bring a complete medication list to every appointment, including OTC supplements, because many natural products (St. John's Wort, for instance) affect the same CYP3A4 pathway and compound interaction risk.

Progesterone's sedating effects come largely from its conversion to allopregnanolone, a neurosteroid that potentiates GABA-A receptors. [10] If progesterone exposure increases due to resmetirom co-administration, patients may notice stronger-than-usual sleepiness within 1 to 2 hours of their evening progesterone dose. Taking oral progesterone at bedtime (standard practice) mitigates daytime sedation risk.

Patients should not stop either medication without consulting their prescribing physician. Abrupt discontinuation of progesterone in a woman with an intact uterus on estrogen HRT removes endometrial protection. Abrupt discontinuation of resmetirom has not been associated with rebound MASH progression in short-term follow-up, but MASH management requires a long-term therapeutic strategy.

What Do Guidelines Say About HRT in MASH?

The American Association for the Study of Liver Diseases (AASLD) 2023 MASH clinical practice guidance does not specifically address concurrent HRT use but notes that "no HRT formulation has been shown to accelerate liver fibrosis progression in women with MASLD/MASH based on available evidence." [12] The Menopause Society (formerly NAMS) 2023 position statement supports individualized HRT decisions in women with liver disease, noting that transdermal or vaginal routes minimize hepatic first-pass exposure and are preferred when hepatic metabolism is a concern. [13]

The FDA prescribing information for Rezdiffra states: "Resmetirom is a moderate inhibitor of CYP3A4. Co-administration with sensitive CYP3A4 substrates may increase their plasma concentrations. Use the lowest effective dose of sensitive CYP3A4 substrates when co-administered with resmetirom." [1] This language is the regulatory basis for dose optimization rather than avoidance.

Special Populations

Women With Child-Pugh B or C Liver Disease

Resmetirom is not approved for use in Child-Pugh B or C hepatic impairment. [1] The MAESTRO-NASH trial excluded patients with decompensated cirrhosis, so there are no safety data for resmetirom plus progesterone in this group. Progesterone itself should be used with caution in severe hepatic impairment because reduced CYP enzyme activity will independently raise progesterone exposure regardless of resmetirom. [9]

Postmenopausal Women on Estrogen Plus Progesterone Regimens

The most common HRT regimen in postmenopausal women is conjugated equine estrogens or estradiol combined with a progestogen. Oral estradiol is also a CYP3A4 substrate, though to a lesser degree than oral progesterone. [3] When both estradiol and progesterone are oral and resmetirom is added, monitoring both hormones or switching both to non-oral routes is a clinically straightforward solution that removes the pharmacokinetic concern with a single prescribing adjustment.

Perimenopausal Women on Cyclic Progesterone

Women using cyclic progesterone (typically 200 mg nightly for 12 to 14 days per month) are exposed to the CYP3A4 interaction only during those cyclic days. The interaction is real but time-limited each month, which makes it less likely to cause sustained accumulation-related adverse effects than continuous daily oral progesterone use.